Raymond James Financial
IMVT icon

Raymond James Financial’s Immunovant IMVT Stock Holding History

Raymond James Financial’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
5,758
-2,499
-30% -$76.1K ﹤0.01% 4997
2026
Q1 		$205K Buy
+8,257
New +$214K ﹤0.01% 4876
2025
Q3 		– Sell
-300
Closed -$4.8K – 5807
2025
Q2 		$4.8K Sell
300
-59,374
-99% -$898K ﹤0.01% 6184
2025
Q1 		$1.02M Buy
59,674
+39,292
+193% +$822K ﹤0.01% 3474
2024
Q4 		$505K Buy
+20,382
New +$578K ﹤0.01% 3901

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's IMVT Position: Q2 2026 in Review

Raymond James Financial reduced its Immunovant (IMVT) stake by 30% in Q2 2026, selling an estimated $76.1K and leaving 5,758 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #4997.

Raymond James Financial first reported a position in IMVT in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.02M in Q1 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Raymond James Financial held 5,758 shares of Immunovant worth $222K as of Q2 2026.
  • Raymond James Financial sold 2,499 Immunovant shares in Q2 2026, an estimated $76.1K.
  • Immunovant made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4997 holding.
  • Raymond James Financial first reported a position in Immunovant in Q4 2024 and has held it in 5 quarters since.
  • Raymond James Financial's Immunovant position peaked at $1.02M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.